Skip to main content
Bonesupport Holding logo

Bonesupport Holding — Investor Relations & Filings

Ticker · BONEX ISIN · SE0009858152 LEI · 549300COLY053IGTLD63 ST Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2021-07-08 Report Publication Anno…
Country SE Sweden
Listing ST BONEX

About Bonesupport Holding

https://www.bonesupport.com/en-eu/

Bonesupport Holding is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes. Its core product platform, CERAMENT®, is an innovative range of osteoconductive and drug-eluting products designed to heal bone defects. A key characteristic of CERAMENT® is its ability to remodel into the patient's own host bone, typically within six to twelve months. The products are used to treat bone voids and defects arising from trauma, infection, disease, or related surgical procedures. The radiopaque nature of the material allows for visualization during and after surgery.

Recent filings

Filing Released Lang Actions
BONESUPPORT HOLDING AB (publ) – Delårsrapport Q2 2021 Inbjudan till konferenssamtal och webbsänding
Report Publication Announcement Classification · 1% confidence The document is titled "BONESUPPORT HOLDING AB (publ) – Delårsrapport Q2 2021 Inbjudan till konferenssamtal och webbsänding" (Interim Report Q2 2021 Invitation to conference call and webcast). It explicitly states that the company will publish its interim report for Q2 2021 on July 15th and then invites stakeholders to a conference call/webcast on the same day at 10:00 CET to discuss the results. Since the document's primary function is to announce the upcoming release of the financial report and invite participants to the subsequent discussion, it fits the definition of a Report Publication Announcement (RPA). The document length is short (2031 chars), supporting the 'MENU VS MEAL' rule, as it is an announcement *about* the report, not the comprehensive report itself (which would likely be classified as IR).
2021-07-08 Swedish
BONESUPPORT HOLDING AB (publ) – Interim Report Q2 2021 Invitation to conference call and webcast
Report Publication Announcement Classification · 1% confidence The document is an announcement dated July 8, 2021, explicitly stating that BONESUPPORT HOLDING AB will publish its 'Interim Report Q2 2021' on July 15, and it invites recipients to a conference call and webcast to discuss those results. Since the document itself is an invitation/announcement about the upcoming release of the financial report (Interim Report Q2 2021) and includes dial-in details, it fits the definition of a Report Publication Announcement (RPA). It is not the full Interim Report (IR) itself, nor is it the transcript of the call (CT). The document length is short (2110 chars), supporting the RPA classification based on the 'MENU VS MEAL' rule.
2021-07-08 English
Change in number of shares and votes in BONESUPPORT Holding AB (publ)
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing a 'Change in number of shares and votes' due to warrant exercises, resulting in a new total number of shares and votes as of June 30, 2021. This directly relates to changes in the company's capital structure and share count. Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for announcements detailing changes in the total number of shares outstanding, even if triggered by warrant conversion rather than a primary issuance. It is not an Earnings Release (ER), Interim Report (IR), or a Director's Dealing (DIRS).
2021-06-30 English
Ändring av antalet aktier och röster i BONESUPPORT Holding AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement from BONESUPPORT Holding AB dated June 30, 2021, detailing a change in the total number of shares and votes due to the exercise of warrants. This directly relates to changes in the company's capital structure (share count). The definitions provided include 'Share Issue/Capital Change (Code: SHA)' for announcements regarding new share issues or capital changes. Although the change resulted from warrant exercise, the core subject is the resulting change in the total number of shares, fitting best under SHA. It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as SHA is more specific. The document length is short (2141 chars), but it is the primary announcement itself, not an announcement *of* another report, so RPA/RNS is less appropriate than SHA.
2021-06-30 Swedish
BONESUPPORT receives "breakthrough device designation" for CERAMENT G for the indication trauma
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific regulatory event: the US FDA granting 'breakthrough device designation' to the company's product, CERAMENT G, for the trauma indication. This is an announcement regarding regulatory status and future submission plans, not a full financial report (like 10-K or IR), an earnings release (ER), or a transcript (CT). Since it is a specific regulatory update that doesn't fit the defined categories like 'Legal Proceedings Report' (LTR) or 'Capital/Financing Update' (CAP), the most appropriate general category for a significant, non-financial regulatory announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS). However, given the context of FDA interaction and regulatory milestones, it is a specific type of corporate news. Since there is no specific category for 'Regulatory Milestone Announcement' or 'FDA Designation', RNS serves as the best fit among the provided options for a general regulatory update.
2021-06-17 English
BONESUPPORT erhåller ”breakthrough device designation” för CERAMENT G för indikationen trauma
Regulatory Filings Classification · 1% confidence The document is a short press release (2656 characters) written in Swedish, announcing that BONESUPPORT received 'breakthrough device designation' from the FDA for CERAMENT G for the indication of trauma. It discusses regulatory progress, future filings, and potential approvals. This type of announcement, which communicates a specific regulatory event or material development outside of standard periodic financial reports (like 10-K or IR), fits best under the general 'Regulatory Filings' category (RNS) as it is a formal, non-financial regulatory update. It is not an Earnings Release (ER), Interim Report (IR), or a specific legal/capital event. Given its nature as a formal, non-periodic regulatory communication, RNS is the most appropriate fit.
2021-06-17 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.